

**FBXL16 Antibody (N-term) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP10438a****Specification**

---

**FBXL16 Antibody (N-term) Blocking peptide - Product Information**

Primary Accession [Q8N461](#)  
Other Accession [NP\\_699181.2](#)

**FBXL16 Antibody (N-term) Blocking peptide - Additional Information**

**Gene ID** 146330

**Other Names**

F-box/LRR-repeat protein 16, F-box and leucine-rich repeat protein 16, FBXL16, C16orf22, FBL16

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**FBXL16 Antibody (N-term) Blocking peptide - Protein Information**

**Name** FBXL16

**Synonyms** C16orf22, FBL16

**Function**

Substrate-recognition component of the SCF (SKP1-CUL1-F-box protein)-type E3 ubiquitin ligase complex.

**FBXL16 Antibody (N-term) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**FBXL16 Antibody (N-term) Blocking peptide - Images****FBXL16 Antibody (N-term) Blocking peptide - Background**

Members of the F-box protein family, such as FBXL16, are characterized by an approximately

40-amino acid F-box motif. SCF complexes, formed by SKP1 (MIM 601434), cullin (see CUL1; MIM603134), and F-box proteins, act as protein-ubiquitin ligases. F-box proteins interact with SKP1 through the F box, and they interact with ubiquitination targets through other protein interaction domains (Jin et al., 2004 [PubMed 15520277]). [supplied by OMIM].

#### **FBXL16 Antibody (N-term) Blocking peptide - References**

Sato, K., et al. Int. J. Oncol. 36(2):479-490(2010) Martin, J., et al. Nature 432(7020):988-994(2004) Jin, J., et al. Genes Dev. 18(21):2573-2580(2004) Daniels, R.J., et al. Hum. Mol. Genet. 10(4):339-352(2001)